Press release
Hemophilia B Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, IND, NDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Hemophilia B Clinical Trials
"Hemophilia B Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hemophilia B Therapeutics Market.
The report provides a detailed description of the Hemophilia B drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Hemophilia B Clinical Trial Activities and Regulatory Developments in the domain @ https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hemophilia B Therapeutics Analysis
Approximately 15+ notable companies are actively engaged in developing therapies for Hemophilia B. Among these, Belief Biomed stands out for advancing its Hemophilia B drug candidates to the most advanced stage of clinical trials, specifically Phase III. This phase represents a crucial stage in the drug development process, where the efficacy and safety of the treatment are rigorously assessed in a larger patient population. Belief Biomed's progress to Phase III underscores the potential significance of its therapeutic approach in addressing the challenges posed by Hemophilia B, reflecting dedication and progress within the field of hematology and rare diseases.
Recent developments in Hemophilia B Pipeline:
• In May 2024, Novo Nordisk A/S has announced results of a Multi-centre, Open-label Trial Evaluating Efficacy, Safety and Pharmacokinetics of Nonacog Beta Pegol When Used for Treatment and Prophylaxis of Bleeding Episodes in Chinese Patients With Haemophilia B.
• In May 2024, ApcinteX Ltd has announced results of a Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Learn More about the Clinical and Commercial Development Activities in the Hemophilia B Therapeutics Domain @
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hemophilia B Companies in the Therapeutics Market Include:
• Shanghai Vitalgen BioPharma
• Belief BioMed
• TiumBio
• Jiangsu Gensciences
• Centessa Pharmaceuticals
• Pfizer
• OPKO Health
• Bayer
• Takeda
• Sanofi
And Many Others
Emerging and Marketed Hemophilia B Therapies Covered in the Report Include:
• BBM-H901: Belief Biomed
• TU7710: TiumBio
• Concizumab: Novo Nordisk
• Fitusiran: Sanofi/Alnylam Pharmaceuticals
• Etranacogene dezaparvovec (AMT-061): CSL Behring/uniQure
• Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
• AMT-060 (AAV5-hFIX): UniQure
• Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Hemophilia B Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Report Covers the Emerging Hemophilia B Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Hemophilia B pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Request for Sample PDF to Understand More About the Hemophilia B Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hemophilia B Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Hemophilia B therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Hemophilia B drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hemophilia B treatment market.
Table of Content
1. Report Introduction
2. Executive Summary
3. Hemophilia B Current Treatment Patterns
4. Hemophilia B - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hemophilia B Late-Stage Products (Phase-III)
7. Hemophilia B Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hemophilia B Discontinued Products
13. Hemophilia B Product Profiles
14. Hemophilia B Companies
15. Hemophilia B Drugs
16. Dormant and Discontinued Products
17. Hemophilia B Unmet Needs
18. Hemophilia B Future Perspectives
19. Hemophilia B Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Esophageal Squamous Carcinoma Market: https://www.delveinsight.com/report-store/esophageal-cancer-market
• Failed Back Surgery Syndrome Market: https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market
• Familial Hypercholesterolemia Market: https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market
• Familial Lipoprotein Lipase Deficiency Pipeline: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Fucosidosis Market: https://www.delveinsight.com/report-store/fucosidosis-market
• Glycogen Storage Disease Market: https://www.delveinsight.com/report-store/glycogen-storage-disease-market
• Head And Neck Cancer Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Her2-negative Breast Cancer Market: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights
• Her2-positive Early Breast Cancer Market: https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Hospital-acquired And Ventilator-associated Bacterial Pneumonia Habp/vabp Market: https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market
• Hpv16+ Cancer Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hypereosinophilic Syndrome Market: https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market
• Hyperkalemia Market: https://www.delveinsight.com/report-store/hyperkalemia-market
• Hypertrophic Cardiomyopathy Market: https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Implantable Infusion Pump Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Intracranial Arterial Diseases Market: https://www.delveinsight.com/report-store/intracranial-arterial-diseases-market
• Lamellar Icthyosis Market: https://www.delveinsight.com/report-store/lamellar-ichthyosis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia B Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, IND, NDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3872228 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Hemophilia
Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
